Last 48 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
AstraZeneca PLC's quarterly P/E stands at 25.0x, up 26.9% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 15.0% YoY to 14.9x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 26.98 | 25.03 | 29.65 | 23.07 | 22.00 | 19.72 | 33.85 | 41.97 | 31.51 | 24.46 | 55.10 | 38.37 | 30.75 |
| — | +26.9% | -12.4% | -45.0% | -30.2% | -19.4% | -38.6% | +9.4% | +2.5% | -19.0% | -6.2% | +50.5% | -78.1% | |
| P/S Ratio | 4.66 | 5.03 | 4.42 | 3.84 | 3.73 | 4.24 | 3.41 | 4.44 | 4.71 | 4.21 | 4.36 | 4.58 | 4.92 |
| — | +18.9% | +29.7% | -13.5% | -20.9% | +0.5% | -21.9% | -3.1% | -4.2% | -16.2% | -7.9% | +20.6% | +5.3% | |
| P/B Ratio | 5.66 | 6.50 | 5.63 | 5.08 | 4.81 | 5.60 | 4.97 | 5.91 | 6.16 | 5.70 | 5.36 | 5.66 | 6.00 |
| — | +16.1% | +13.3% | -14.0% | -21.9% | -1.8% | -7.3% | +4.3% | +2.6% | -6.7% | -6.5% | +19.2% | +7.3% | |
| P/FCF | 23.25 | 42.27 | 49.79 | 13.12 | 36.81 | 17.52 | 26.01 | 29.75 | 25.22 | 60.63 | 36.59 | 23.57 | 45.44 |
| — | +141.2% | +91.4% | -55.9% | +46.0% | -71.1% | -28.9% | +26.2% | -44.5% | +84.5% | +27.1% | +2.7% | -36.3% | |
| EV / EBITDA | 15.28 | 14.89 | 16.60 | 12.56 | 12.31 | 12.94 | 20.70 | 17.06 | 16.79 | 13.75 | 22.71 | 18.11 | 16.66 |
| — | +15.0% | -19.8% | -26.4% | -26.7% | -5.9% | -8.9% | -5.8% | +0.8% | -8.7% | -9.4% | -2.6% | -44.1% | |
| EV / EBIT | 21.65 | 19.40 | 24.03 | 17.53 | 16.91 | 17.11 | 27.17 | 29.29 | 23.80 | 18.70 | 43.34 | 28.67 | 24.68 |
| — | +13.4% | -11.5% | -40.2% | -29.0% | -8.5% | -37.3% | +2.2% | -3.5% | -19.4% | -17.4% | -24.6% | -75.6% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
AstraZeneca PLC's operating margin was 27.8% in Q1 2026, up 8.6 pp QoQ and up 0.7 pp YoY. The trailing four-quarter average of 23.7% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.9% | 82.5% | 79.9% | 81.6% | 82.9% | 83.5% | 81.7% | 77.3% | 83.1% | 82.5% | 80.8% | 81.8% | 82.8% |
| — | -1.2% | -2.2% | +5.5% | -0.3% | +1.2% | +1.1% | -5.5% | +0.4% | +0.0% | +9.0% | +12.2% | +14.8% | |
| Operating Margin | 23.4% | 27.8% | 19.2% | 23.6% | 24.3% | 27.0% | 13.7% | 15.5% | 21.2% | 24.6% | 10.3% | 17.0% | 21.5% |
| — | +2.7% | +40.5% | +51.9% | +14.3% | +10.1% | +33.2% | -8.7% | -1.3% | +4.9% | +5.1% | +50.0% | +329.9% | |
| Net Margin | 17.5% | 20.1% | 15.0% | 16.7% | 16.9% | 21.5% | 10.1% | 10.5% | 14.9% | 17.2% | 8.0% | 12.0% | 15.9% |
| — | -6.1% | +48.9% | +58.3% | +13.8% | +24.9% | +26.2% | -11.9% | -6.5% | +3.7% | -0.7% | -19.9% | +376.5% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.9% | 6.4% | 4.9% | 5.6% | 5.7% | 7.1% | 3.7% | 3.6% | 5.0% | 5.7% | 2.5% | 3.7% | 5.0% |
| — | -9.9% | +33.8% | +57.0% | +14.1% | +25.1% | +46.1% | -3.5% | +0.7% | +14.9% | +0.7% | -20.2% | +398.7% | |
| ROA | 9.4% | 2.7% | 2.0% | 2.2% | 2.2% | 2.8% | 1.4% | 1.4% | 1.9% | 2.1% | 1.0% | 1.4% | 1.9% |
| — | -2.6% | +41.8% | +63.5% | +20.1% | +29.4% | +47.5% | -4.3% | -0.9% | +14.8% | +3.0% | -17.0% | +414.4% | |
| ROIC | 14.9% | 4.3% | 3.1% | 3.8% | 3.8% | 4.1% | 2.3% | 2.4% | 3.2% | 3.7% | 1.5% | 2.4% | 3.0% |
| — | +5.0% | +35.9% | +61.3% | +20.6% | +11.8% | +52.4% | -1.3% | +5.2% | +17.4% | +10.3% | +54.6% | +354.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
AstraZeneca PLC's Debt/EBITDA ratio is 6.0x, down from 6.6x last quarter — elevated, raising questions about debt serviceability.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.61 | 0.72 | 0.61 | 0.71 | 0.73 | 0.77 | 0.74 | 0.77 | 0.85 | 0.92 | 0.73 | 0.77 | 0.80 |
| — | -7.2% | -17.3% | -8.1% | -13.5% | -16.3% | +0.8% | +0.7% | +6.2% | +4.7% | -7.4% | -7.9% | -2.9% | |
| Debt / EBITDA | 1.53 | 6.04 | 6.62 | 6.36 | 6.71 | 6.40 | 10.95 | 8.05 | 8.33 | 7.91 | 11.18 | 8.83 | 8.00 |
| — | -5.5% | -39.6% | -20.9% | -19.5% | -19.1% | -2.0% | -8.9% | +4.2% | +1.7% | -10.2% | -22.3% | -48.7% | |
| Current Ratio | 0.94 | 0.91 | 0.94 | 0.88 | 0.86 | 0.90 | 0.93 | 0.93 | 0.89 | 0.89 | 0.82 | 0.79 | 0.87 |
| — | +1.3% | +1.2% | -5.6% | -2.9% | +1.3% | +13.0% | +18.4% | +2.7% | -1.1% | -4.5% | -3.3% | -9.7% | |
| Quick Ratio | 0.72 | 0.71 | 0.72 | 0.69 | 0.67 | 0.70 | 0.74 | 0.71 | 0.69 | 0.70 | 0.64 | 0.60 | 0.67 |
| — | +1.7% | -1.8% | -3.9% | -3.0% | -0.8% | +14.7% | +18.5% | +2.4% | +0.7% | -5.6% | -1.2% | +0.1% | |
| Interest Coverage | 8.32 | 10.96 | 6.57 | 8.47 | 8.12 | 10.75 | 4.88 | 5.00 | 6.41 | 7.78 | 3.02 | 5.21 | 5.84 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Deep dive into AZN consensus models and risk factors.
Wall Street verdict, signals, and target summaries.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AZN stock.
AstraZeneca PLC's current P/E is 27.0x. The average P/E over the last 4 quarters is 24.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
AstraZeneca PLC's current operating margin is 23.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking AstraZeneca PLC's business trajectory between earnings reports.